









Markets
/
Stocks
/
nasdaq-abus
/

Arbutus Biopharma Corp

ABUS

4.500USD

+0.060+1.35%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

862.39MMarket Cap

LossP/E TTM



Arbutus Biopharma Corp

4.500

+0.060+1.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arbutus Biopharma Corp

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arbutus Biopharma Corp's Score

Industry at a Glance

Industry Ranking

56 / 407

Overall Ranking

171 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.250

Target Price

+16.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Arbutus Biopharma Corp Highlights

StrengthsRisks

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.17M.

Undervalued

The company’s latest PE is -15.81, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 120.16M shares, increasing 3.55% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 12.57K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.86, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 10.74M, representing a year-over-year increase of 522.19%, while its net profit experienced a year-over-year increase of 112.74%.

Score

Industry at a Glance

Previous score

7.86

Change



Financials

8.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Arbutus Biopharma Corp's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.88, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -15.81, which is -77.07% below the recent high of -3.62 and -8.89% above the recent low of -17.21.

Score

Industry at a Glance

Previous score

6.88

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Arbutus Biopharma Corp is 5.00, with a high of 7.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.250

Target Price

+16.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Arbutus Biopharma Corp

ABUS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 4.93 and the support level at 4.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.16

Change

0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.029

Neutral

RSI(14)

51.417

Neutral

STOCH(KDJ)(9,3,3)

34.467

Sell

ATR(14)

0.211

High Vlolatility

CCI(14)

-46.659

Neutral

Williams %R

64.964

Sell

TRIX(12,20)

0.241

Sell

StochRSI(14)

33.339

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.526

Sell

MA10

4.586

Sell

MA20

4.494

Buy

MA50

4.395

Buy

MA100

3.860

Buy

MA200

3.598

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 62.68%, representing a quarter-over-quarter decrease of 23.15%. The largest institutional shareholder is The Vanguard, holding a total of 9.05M shares, representing 4.72% of shares outstanding, with 0.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Roivant Sciences Ltd.

38.85M

Morgan Stanley Investment Management Inc. (US)

23.06M

+1.61%

Whitefort Capital Management, LP

13.34M

+0.26%

BlackRock Institutional Trust Company, N.A.

11.47M

+0.52%

Two Seas Capital LP

10.44M

+10.33%

The Vanguard Group, Inc.

Star Investors

9.05M

+1.47%

State Street Investment Management (US)

4.46M

+2.21%

Geode Capital Management, L.L.C.

3.64M

+2.71%

Goldman Sachs & Company, Inc.

3.00M

+47.80%

Adar1 Capital Management LLC

2.83M

+50.38%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 5.62, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.